We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

44 hedge funds and large institutions have $15.5M invested in Relmada Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

389% more capital invested

Capital invested by funds: $3.18M → $15.5M (+$12.4M)

18% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 11

7.34% more ownership

Funds ownership: 15.98% → 23.32% (+7.3%)

12% less funds holding

Funds holding: 50 → 44 (-6)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
44
Holders Change
-6
Holders Change %
-12%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
13
Reduced
11
Closed
8
Calls
$282K
Puts
–
Net Calls
+$282K
Net Calls Change
+$267K

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$1.73M
2
BFM
Boothbay Fund Management
New York
+$665K
3
Marshall Wace
Marshall Wace
United Kingdom
+$113K
4
Two Sigma Investments
Two Sigma Investments
New York
+$75K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$69.7K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$116K
2
ACM
ADAR1 Capital Management
Texas
-$78K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$35.4K
4
XT
XTX Topco
Cayman Islands
-$27.6K
5
Jane Street
Jane Street
New York
-$27.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
26
AlTi Global
New York
$64.3K – – –
RSWM
27
Robertson Stephens Wealth Management
California
$50.3K – – –
PW
28
Pandora Wealth
Illinois
$40.2K – – –
TIM
29
Tortoise Investment Management
New York
$28K -$7.45K -7,767 -36%
Lido Advisors
30
Lido Advisors
California
$27.9K – – –
WIA
31
World Investment Advisors
California
$21.4K -$10.6K -11,000 -51%
BFC
32
Bedel Financial Consulting
Indiana
$20.1K – – –
Barclays
33
Barclays
United Kingdom
$20.1K +$9.59K +9,999 +999,900%
ACA
34
American Capital Advisory
Idaho
$3.93K – – –
TRCT
35
Tower Research Capital (TRC)
New York
$3.18K -$4.42K -4,608 -74%
Morgan Stanley
36
Morgan Stanley
New York
$2.09K +$179 +187 +22%
FFA
37
Farther Finance Advisors
California
$1.68K +$804 +838 New
Bank of America
38
Bank of America
North Carolina
$528 -$59 -61 -19%
SS
39
SBI Securities
Japan
$205 – – –
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$187 +$6 +6 +7%
Osaic Holdings
41
Osaic Holdings
Arizona
$9 – – –
FRA
42
Front Row Advisors
California
$4 -$1 -1 -33%
Citigroup
43
Citigroup
New York
$4 – – –
ACM
44
ADAR1 Capital Management
Texas
– -$78K -130,000 Closed
XT
45
XTX Topco
Cayman Islands
– -$27.6K -46,039 Closed
WIA
46
Wealthedge Investment Advisors
New York
– -$16.8K -28,000 Closed
Group One Trading
47
Group One Trading
Illinois
– -$25.2K -26,301 Closed
GSC
48
Ground Swell Capital
South Carolina
– -$9.2K -15,320 Closed
HF
49
HRT Financial
New York
– -$7K -12,162 Closed
JP Morgan Chase
50
JP Morgan Chase
New York
– -$3.06K -5,103 Closed
1
2
3

RLMD Hedge Fund Activity: Q3 2025 in Review

44 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2025, worth a combined $15.5M — up 389% from $3.18M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of RLMD and 2 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 13 added.

The largest buyer was Ikarian Capital, adding an estimated $1.73M. The largest seller was UBS Group, cutting an estimated $116K.

  • 44 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2025, down from 50 in Q2 2025.
  • Funds reported $15.5M of Relmada Therapeutics stock for Q3 2025, up 389% quarter-over-quarter.
  • 2 funds opened new Relmada Therapeutics positions in Q3 2025 and 8 closed out, a net change of -6 holders.
  • The largest Relmada Therapeutics buyer in Q3 2025 was Ikarian Capital, an estimated $1.73M added.
  • The largest Relmada Therapeutics seller in Q3 2025 was UBS Group, an estimated $116K sold.

Based on aggregated 13F filings for Q3 2025.